Combioxin

Phase 1

Epalinges, SwitzerlandFounded 2013combioxin.com

Combioxin is dedicated to revolutionizing the treatment of severe infections and immune dysfunction in intensive care. Its core technology uses proprietary engineered liposomes to capture and neutralize bacterial toxins, offering a novel mechanism against both Gram-positive and Gram-negative pathogens. The company has achieved significant regulatory milestones for CAL02, initiated a global Phase 2b study, and secured a worldwide out-licensing agreement with Eagle Pharmaceuticals, positioning it to address a critical unmet medical need with high mortality and cost.

Founded

2013

Focus

Biologics

AI Company Overview

Technology Platform

Proprietary engineered liposomes designed to capture and neutralize bacterial virulence factors (toxins), offering a broad-spectrum, anti-virulence mechanism of action applicable to severe infections and immune dysfunction.

Pipeline Snapshot

1 drug in pipeline

Drug	Indication	Stage
CAL02 Low-dose + CAL02 High-dose + Placebo	Pneumonia	Phase 1

Funding History

Total raised: $17.5M

Series A$15MNovartis Venture FundMar 15, 2023

Seed$2.5MZurcher KantonalbankJun 15, 2021

Opportunities

CAL02 addresses a multi-billion dollar market in severe pneumonia with high mortality and no approved adjunctive therapies.

Success could establish a new standard of care.

The immunoparalysis program targets a completely untapped market in critical care immunosuppression, with potential applications beyond sepsis.

Risk Factors

Clinical failure in the ongoing Phase 2b trial for CAL02 is the primary near-term risk.

Regulatory hurdles for a first-in-class agent and future market adoption against entrenched standard care (antibiotics alone) present commercial challenges.

The company's private status implies dependency on partnership milestones or future financing rounds.

Competitive Landscape

For CAL02, competition includes late-stage antibiotics and failed sepsis immunomodulators; differentiation lies in its broad-spectrum, anti-virulence mechanism. In immunoparalysis, there are virtually no direct competitors, positioning Combioxin as a pioneer. The partnership with Eagle Pharmaceuticals provides a commercial advantage.